Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Black Bird Biotech, Inc. (BBBT)
Argyle, TX, US
Black Bird Biotech Inc. operates within the biotechnology sector, offering a diverse array of products. A key offering is MiteXstream, a unique plant-derived biopesticide manufactured and distributed by the company, specifically formulated to eradicate spider mites. The company further diversifies its portfolio with a range of consumer goods sold under its Grizzly Creek Naturals brand. These include CBD oils, gummies, and pet treats, as well as CBD-infused personal care items and both gel and spray hand sanitizer products. Beyond these offerings, Black Bird Biotech also engages in the cultivation of industrial hemp, participating in the Montana Hemp pilot program. The entity, headquartered in Flower Mound, Texas, underwent a name change in June 2021, transitioning from its former identity as Digital Development Partners, Inc. to its current Black Bird Biotech, Inc. designation.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -66.67% | -99.71% | -97.78% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-21.0% Q3'23: -84.7% (vs Q3'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+46.2% ★ Q3'23: +87.5% (vs Q3'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-1,698.9% Q3'23: -124.5% (vs Q3'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-1,560.2% Q3'23: -273.3% (vs Q3'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q3'23: +23.9% (vs Q3'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+70.1% Q3'23: +334.7% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.56× Q3'23: 4.48× (vs Q3'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2009-01-15 | Collins Jeffrey A | Officer | — | D | Common Stock | 0 | 0.00 | — | 1,500,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fabian G. Deneault | Chairman of the Board & President | 90.0K | male |
| Eric Newlan | Vice President, Secretary & Director | 80.0K | male |
| William E. Sluss | Chief Financial Officer, Vice President of Finance & Director | 60.0K | male |
| Nelson Grist | Chief Executive Officer | — | male |
| William J. LoBell | Executive Vice President of Sales & Development | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BBBT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
